Aviance Capital Partners LLC Has $916,000 Stock Position in Danaher Co. (NYSE:DHR)

Aviance Capital Partners LLC lifted its stake in shares of Danaher Co. (NYSE:DHR) by 65.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,670 shares of the conglomerate’s stock after buying an additional 1,456 shares during the period. Aviance Capital Partners LLC’s holdings in Danaher were worth $916,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Tsfg LLC grew its holdings in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. Cape Investment Advisory Inc. acquired a new stake in Danaher in the fourth quarter valued at $25,000. BKM Wealth Management LLC acquired a new stake in Danaher in the fourth quarter valued at $27,000. Wetzel Investment Advisors Inc. bought a new position in Danaher during the 4th quarter worth $29,000. Finally, Rakuten Securities Inc. acquired a new position in Danaher during the 4th quarter worth about $36,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of DHR opened at $244.51 on Tuesday. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $269.11. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The stock has a 50 day moving average price of $255.96 and a two-hundred day moving average price of $246.75. The firm has a market capitalization of $181.11 billion, a P/E ratio of 41.44, a P/E/G ratio of 3.82 and a beta of 0.84.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the prior year, the firm posted $2.36 EPS. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. Equities analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insiders Place Their Bets

In related news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares in the company, valued at $7,457,798.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares in the company, valued at approximately $28,352,350. The disclosure for this sale can be found here. Insiders have sold a total of 148,783 shares of company stock valued at $37,536,717 in the last 90 days. 10.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on DHR. Citigroup upped their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. TD Cowen increased their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, Bank of America boosted their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.